COLORADO SPRINGS, Colo., July 13, 2017 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) (“the Company”) today announced that it will release
financial results for the second quarter ended June 30, 2017, after market close on August 3, 2017. Due to the pending transaction
with Royal Philips, the Company will not hold an earnings call to discuss the results.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive
procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat
arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above
and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated
balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets
support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire
retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets
aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for
the removal of pacemaker and defibrillator cardiac leads, including the Bridge™ Occlusion Balloon.
For more information, visit www.spectranetics.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of
the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. You can identify these statements
because they do not relate strictly to historical or current facts. Such statements may include words such as “anticipate,” “will,”
“estimate,” “expect,” “look forward,” “strive,” “project,” “intend,” “should,” “plan,” “believe,” “hope,” “see,” “enable,”
“potential,” “pending” and other words and terms of similar meaning in connection with any discussion of, among other things,
future operating or financial performance, strategic initiatives and business strategies, clinical trials and regulatory approvals,
regulatory or competitive environments, outcome of litigation, our intellectual property and product development. These
forward-looking statements include, but are not limited to, statements regarding our competitive position, product innovation and
development, and commercialization schedule, expectation of continued growth and the reasons for that growth, growth rates,
strength, integration and product launches, regulatory approvals, and 2017 outlook and projected results including projected
revenue and expenses, gross margin, net loss and loss per share. Such statements are based on current assumptions that involve
risks and uncertainties that could cause actual outcomes and results to differ materially. You are cautioned not to place undue
reliance on these forward-looking statements and to note they speak only as of the date of this release. These risks and
uncertainties may include financial results differing from guidance; our need to comply with complex and evolving laws and
regulations; intense and increasing competition and consolidation in our industry; the impact of rapid technological change; slower
revenue growth and continued losses; the inaccuracy of our assumptions regarding AngioScore and Stellarex; market acceptance of our
technology and products; our inability to manage growth; increased pressure on expense levels resulting from expanded sales,
marketing, product development and clinical activities; uncertain success of our strategic direction; dependence on new product
development and successful commercialization of new products; loss of key personnel; uncertain success of or delays in our clinical
trials; costs of and adverse results in any ongoing or future legal proceedings; adverse impact to our business from healthcare
reform and related legislation and regulations, including changes in reimbursements and the impact of fraud and abuse and
information privacy laws and regulations; adverse conditions in the general domestic and global economic markets and volatility and
disruption of the credit markets or other factors that prevent us from obtaining funding; our inability to protect our intellectual
property and intellectual property claims of third parties; availability of inventory and components from suppliers, including sole
source suppliers; adverse outcome of FDA inspections, including FDA warning letters and any remediation efforts; the receipt of FDA
clearance and other regulatory approvals to market new products or applications and the timeliness of any clearance and approvals;
product defects or recalls and product liability claims; cybersecurity breaches; interruptions of our manufacturing operations and
other events that affect our ability to manufacture sufficient volumes to fulfill customer demand; our dependence on third party
vendors, suppliers, consultants and physicians; risks associated with international operations, including international sales using
distributors and the impact of “Brexit” on our European sales and operations; risks associated with any future acquisitions; our
ability to use net operating loss carryovers and potential impairment charges; lack of cash necessary to satisfy our cash
obligations under our outstanding 2.625% Convertible Senior Notes due 2034 and our term loan and revolving loan facilities; our
debt adversely affecting our financial health and preventing us from fulfilling our debt service and other obligations; and share
price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list
and description of such risks and uncertainties that could cause our actual results, performance or achievements to materially
differ from any anticipated results, performance or achievements, please see our previously filed SEC reports, including those
risks set forth in our 2016 Annual Report on Form 10-K and Forms 10Q. We disclaim any intention or obligation to update or revise
any financial or other projections or other forward-looking statements, whether because of new information, future events or
otherwise.
Investor Relations Contacts Zach Stassen Investor.relations@spnc.com 719-447-2292 Michaella Gallina Investor.relations@spnc.com 719-447-2417
